单激素受体阳性乳腺癌的临床特点及预后研究

目的探讨单激素受体阳性乳腺癌的临床病理及预后特点。方法选取2000年1月-2004年12月就诊的Ⅰ~Ⅲ期乳腺癌568例,其中雌激素受体（estrogen receptor,ER）单阳型乳腺癌80例和孕激素受体（progesterone receptor,PR）单阳型乳腺癌58例（共138例）,分析两组单激素受体乳腺癌的临床病理特征及预后特点。结果 PR单阳型组年龄≤50岁以及绝经前患者比例显著高于ER单阳型组（P〈0.05）;ER及PR单阳型乳腺癌的无病生存期（disease-free survival,DFS）、总生存期（oerall survival,OS）差异无统计学意义（P〉0.05）;ER单阳型组的DFS、OS明显优于双阴型乳腺癌（P〈0.05）,但PR单阳型组与其差异无统计学意义（P〉0.05）;PR单阳型组的DFS及OS较双阳型乳腺癌显著缩短（P〈0.05）,而ER单阳型组与其差异无统计学意义（P〉0.05）。结论 PR单阳型乳腺癌更多见于年轻、绝经前女性,与ER单阳型乳腺癌的生存期差异无统计学意义;PR单阳型乳腺癌的预后接近于双阴型乳腺癌,而ER单阳型乳腺癌则更接近于双阳型乳腺癌。

Clinical and prognostic characteristics of single hormone receptor positive breast cancer

Objective To analyze the clinical and prognostic characteristics of single hormone receptor positive breast cancer.Methods Five hundred and sixty eihgtⅠ—Ⅲ breast cancer patients include 80 ER+/PR-subjects and 58 ER-/PR+ subjects admitted to Naval General Hospital from January 2000 to December 2004 were enrolled in this study.The clinical and prognostic character were compared.Results ER-/PR + tumors were found more frequently in younger,premenopausal women(P<0.05).Survival analyses showed no difference between ER+/PR-and ER-/PR+ tumor in terms of disease-free interval and overall survival(P>0.05).However,when compared with the double-negative phenotype,the ER+/PR-patients showed an association with better outcome but no survival advantage was detected in case of ER-/PR+ tumors.When compared with the double-positive phenotype,the ER-/PR+ group showed worse outcome whereas no such survival difference was detected in ER+/PR-tumors.Conclusion ER-/PR+ tumors are found more frequently in younger,premenopausal women,and its outcome is close to double-negative tumors;whereas ER+/PR-tumors outcome is close to double-positive tumors.